EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase III)

Exagamglogene Autotemcel for Severe Sickle Cell Disease

Haydar Frangoul iD, Franco Locatelli iD, Akshay Sharma iD, Monica Bhatia, Markus Mapara, Lyndsay Molinari, Donna Wall, Robert I Liem, Paul Telfer, Ami J Shah, Marina Cavazzana, Selim Corbacioglu iD und 17 weitere

New England Journal of Medicine · 09.05.2024 · 390 (18) · 1649-1662

DOI: 10.1056/nejmoa2309676 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift New England Journal of Medicine, erschienen am 09.05.2024. Verfasst von Haydar Frangoul und 28 weiteren Autor:innen. Beteiligte Einrichtung: From Sarah Cannon Research Institute at the Children's Hospital at TriStar Centennial (H.F.), Nashville, and Bone Marrow Transplantation and Cellular…. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Fetal Hemoglobin, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 527-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Vertex Pharmaceuticals, CRISPR Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellFetal HemoglobinHematopoietic Stem Cell TransplantationAdolescentAdultChildFemaleHumansMaleYoung AdultAntigens, CD34BusulfanCRISPR-Cas SystemsGene EditingHematopoietic Stem CellsRepressor ProteinsTransplantation ConditioningCell- and Tissue-Based TherapyMyeloablative AgonistsEuropeNorth America

Substanzen

Antigens, CD34BusulfanFetal HemoglobinRepressor ProteinsMyeloablative AgonistsBCL11A protein, human

Autor:innen und Institutionen

  • From Sarah Cannon Research Institute at the Children's Hospital at TriStar Centennial (H.F.), Nashville, and Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis (A.S.) - both…

ORCID-Profile: Haydar Frangoul, Franco Locatelli, Akshay Sharma, Selim Corbacioglu, Mark C Walters

Förderung

  • Vertex Pharmaceuticals
  • CRISPR Therapeutics

Zitieren

APA

Frangoul, H., Locatelli, F., Sharma, A., Bhatia, M., Mapara, M., Molinari, L., Wall, D., Liem, R. I., Telfer, P., Shah, A. J., Cavazzana, M., Corbacioglu, S., Rondelli, D., Meisel, R., Dedeken, L., Lobitz, S., de Montalembert, M., Steinberg, M. H., Walters, M. C., …, & CLIMB SCD-121 Study Group (2024). Exagamglogene Autotemcel for Severe Sickle Cell Disease. New England Journal of Medicine, 390(18), 1649-1662. https://doi.org/10.1056/nejmoa2309676

Vancouver

Frangoul H, Locatelli F, Sharma A, Bhatia M, Mapara M, Molinari L, et al. Exagamglogene Autotemcel for Severe Sickle Cell Disease. New England Journal of Medicine. 2024;390(18):1649-1662. doi:10.1056/nejmoa2309676

BibTeX
@article{Frangoul2024,
  author = {Frangoul, Haydar and Locatelli, Franco and Sharma, Akshay and Bhatia, Monica and Mapara, Markus and Molinari, Lyndsay and Wall, Donna and Liem, Robert I and Telfer, Paul and Shah, Ami J and Cavazzana, Marina and Corbacioglu, Selim and Rondelli, Damiano and Meisel, Roland and Dedeken, Laurence and Lobitz, Stephan and de Montalembert, Mariane and Steinberg, Martin H and Walters, Mark C and Eckrich, Michael J and Imren, Suzan and Bower, Laura and Simard, Christopher and Zhou, Weiyu and Xuan, Fengjuan and Morrow, Phuong Khanh and Hobbs, William E and Grupp, Stephan A and CLIMB SCD-121 Study Group, CLIMB SCD-121 Study Group},
  title = {Exagamglogene Autotemcel for Severe Sickle Cell Disease},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {390},
  number = {18},
  pages = {1649--1662},
  doi = {10.1056/nejmoa2309676}
}
Kostenlos starten →